Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
CVRx, Inc. (CVRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CVRX at 28.1/100 on a 32-signal composite quality model, placing it at rank #2,569 of 2,962 stocks — the bottom half of the AI-ranked universe. CVRX scores in the top quartile across revenue growth (79.7). Areas of concern include balance sheet strength (3.7) and free cash flow (7.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 9.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CVRx, Inc. reports quarterly revenue of $15.7M, net income of $-14.0M, an operating margin of -82.9%. Top institutional holders of CVRX by reported 13-F value include JOHNSON & JOHNSON, NEA Management Company, BlackRock, based on the most recent SEC filings. CVRX trades on the Nasdaq exchange and files with the SEC under CIK 1235912. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CVRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CVRx, Inc. directly from SEC EDGAR.
AI Quality Score
28.1/100
AI Rank
#2,569
Revenue
$15.7M
Net Income
$-14.0M
Free Cash Flow
$-8.9M
Operating Margin
-82.9%
| Period | Form | Revenue | Net income | Operating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $56.7M | $-53.3M | -90.5% |
| FY 2024 | 10-K | $51.3M | $-60.0M | -116.0% |
| FY 2023 | 10-K | $39.3M | $-41.2M | -109.7% |
| FY 2022 | 10-K | $22.5M | $-41.4M | -189.3% |
| FY 2021 | 10-K | $13.0M | $-43.1M | -199.2% |
| FY 2020 | 10-K | $6.1M | $-14.1M | -190.2% |
| Institution | Shares | Value | Reported |
|---|---|---|---|
| JOHNSON & JOHNSON | 4,024,861 | $20.7M | 2026-06-30 |
| NEA Management Company | 1,954,440 | $10.0M | 2026-06-30 |
| BlackRock | 1,245,459 | $6.4M | 2026-06-30 |
| ROYAL BANK OF CANADA | 1,233,212 | $6.3M | 2026-06-30 |
| GSK plc | 1,007,583 | $5.2M | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT | 910,576 | $4.7M | 2026-06-30 |
| SILVERCREST ASSET MANAGEMENT GROUP | 878,109 | $4.5M | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT | 440,786 | $2.3M | 2026-06-30 |
| PFM Health Sciences | 369,572 | $1.9M | 2026-06-30 |
| STATE STREET | 366,352 | $1.9M | 2026-06-30 |
13F Pro Quality Score
Rank #2,569 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk